[144] DexCom, Inc. SEC Filing

Rhea-AI Filing Summary

DexCom (NASDAQ: DXCM) Officer Sadie Stern has filed a Form 144 notice indicating a proposed sale of 1,466 shares of common stock with an aggregate market value of $124,697.96. The planned transaction is scheduled for execution on June 26, 2025, through Morgan Stanley Smith Barney LLC.

The shares to be sold were acquired as Restricted Stock from the issuer on November 19, 2023. The filing also discloses Stern's recent trading activity, showing three previous sales in May 2025 totaling 6,184 shares with combined gross proceeds of $526,318.38.

The transaction is being executed under a Rule 10b5-1 trading plan adopted on February 20, 2025. As of the filing date, DexCom has 392,107,501 shares outstanding. The seller has certified no knowledge of material adverse non-public information regarding the company's operations.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK	0001797971
Filer CCC	XXXXXXXX
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer	DEXCOM, INC.
SEC File Number	000-51222
Address of Issuer	6340 Sequence Drive San Diego CALIFORNIA 92121
Phone	(858) 200-0200
Name of Person for Whose Account the Securities are To Be Sold	SADIE STERN
See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.
Relationship to Issuer	Officer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Morgan Stanley Smith Barney LLC Executive Financial Services 1 New York Plaza 8th Floor New York NY 10004	1466	124697.96	392107501	06/26/2025	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	11/19/2023	Restricted Stock	ISSUER			1466	11/19/2023	Not Applicable

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
SADIE STERN 6340 Sequence Drive San Diego CA 92121	Common	05/27/2025	682	58044.82
SADIE STERN 6340 Sequence Drive San Diego CA 92121	Common	05/27/2025	784	66726.00
SADIE STERN 6340 Sequence Drive San Diego CA 92121	Common	05/27/2025	4718	401547.56

144: Remarks and Signature

Remarks
Date of Notice	06/26/2025
Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1	02/20/2025
ATTENTION:
The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
Signature	/s/ Sadie Stern
ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

How many DXCM shares is Sadie Stern planning to sell according to the Form 144 filing from June 28, 2025?

According to the Form 144 filing, Sadie Stern, an officer at DexCom, plans to sell 1,466 shares of DXCM common stock with an aggregate market value of $124,697.96 through Morgan Stanley Smith Barney LLC.

What was the total value of DXCM shares sold by Sadie Stern in the past 3 months before this Form 144 filing?

In the three months prior to this filing, Sadie Stern sold a total of 6,184 DXCM shares in three separate transactions on May 27, 2025, generating total gross proceeds of $526,318.38.

When did Sadie Stern acquire the DXCM shares mentioned in this Form 144?

The shares were acquired on November 19, 2023, as restricted stock directly from the issuer (DexCom). The filing indicates 1,466 shares were acquired on this date.

Does DXCM executive Sadie Stern's Form 144 filing indicate a 10b5-1 trading plan?

Yes, the filing indicates that Stern is relying on a Rule 10b5-1 trading plan that was adopted on February 20, 2025. This suggests the planned sale is part of a predetermined trading schedule.

What is the current number of outstanding DXCM shares according to the June 2025 Form 144?

According to the Form 144 filing, DexCom (DXCM) has 392,107,501 shares outstanding as of the filing date.